Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aytu Biopharma Inc AYTU

Healthcare
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended... see more

Recent & Breaking News (NDAQ:AYTU)

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Accesswire November 7, 2023

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Accesswire October 26, 2023

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Accesswire October 9, 2023

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

Accesswire September 26, 2023

Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023

Accesswire September 21, 2023

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

Accesswire September 13, 2023

Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline

Newsfile August 8, 2023

Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority

Accesswire July 31, 2023

Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Accesswire July 10, 2023

Aytu to Participate in the Maxim Group Virtual Healthcare Conference

Accesswire June 14, 2023

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

Accesswire June 13, 2023

Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director

Accesswire June 9, 2023

Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results

Accesswire May 11, 2023

Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023

Accesswire May 4, 2023

Aytu BioPharma Subleases a Portion of Its Manufacturing Facility

Accesswire May 1, 2023

Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer

Accesswire April 27, 2023

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023

Accesswire February 21, 2023

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023

Accesswire February 21, 2023

Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results

Accesswire February 14, 2023

Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023

Accesswire February 7, 2023